PMID- 26665003
OWN - NLM
STAT- MEDLINE
DCOM- 20160915
LR  - 20181113
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2015
DP  - 2015
TI  - Effects of Etanercept against Transient Cerebral Ischemia in Diabetic Rats.
PG  - 189292
LID - 10.1155/2015/189292 [doi]
LID - 189292
AB  - Diabetes mellitus is known to exacerbate acute cerebral ischemic injury. Previous 
      studies have demonstrated that infarction volumes caused by transient cerebral 
      ischemia were greater in diabetic rats than in nondiabetic rats. Tumor necrosis 
      factor-alpha (TNF-alpha) is a proinflammatory protein produced in the brain in response 
      to cerebral ischemia that promotes apoptosis. Etanercept (ETN), a recombinant TNF 
      receptor (p75)-Fc fusion protein, competitively inhibits TNF-alpha. Therefore, we 
      evaluated the neuroprotective effects of chronic or acute treatment with ETN on 
      cerebral injury caused by middle cerebral artery occlusion/reperfusion (MCAO/Re) 
      in rats with streptozotocin-induced diabetes. Furthermore, we evaluated the 
      effects of ETN against the apoptosis and myeloperoxidase activity. Single 
      administration of ETN before MCAO significantly suppressed exacerbation of 
      cerebral damage in nondiabetic rats, as assessed by infarct volume. In contrast, 
      the diabetic state markedly aggravated MCAO/Re-induced cerebral damage despite 
      ETN treatment within 24 h before MCAO. However, the damage was improved by 
      repeated administration of ETN at 900 mug/kg/daily in rats in an induced diabetic 
      state. These results suggested that repeated administration of ETN can prevent 
      exacerbation of cerebral ischemic injury in the diabetic state and is mainly 
      attributed to anti-inflammatory effects.
FAU - Iwata, Naohiro
AU  - Iwata N
AD  - Laboratory of Immunobiochemistry, Department of Clinical Dietetics & Human 
      Nutrition, Faculty of Pharmaceutical Sciences, Josai University, Saitama 
      350-0295, Japan.
FAU - Takayama, Hiroko
AU  - Takayama H
AD  - Laboratory of Immunobiochemistry, Department of Clinical Dietetics & Human 
      Nutrition, Faculty of Pharmaceutical Sciences, Josai University, Saitama 
      350-0295, Japan.
FAU - Xuan, Meiyan
AU  - Xuan M
AD  - Laboratory of Organic and Medicinal Chemistry, School of Pharmaceutical Sciences, 
      Faculty of Pharmaceutical Sciences, Josai University, Saitama 350-0295, Japan.
FAU - Kamiuchi, Shinya
AU  - Kamiuchi S
AD  - Laboratory of Immunobiochemistry, Department of Clinical Dietetics & Human 
      Nutrition, Faculty of Pharmaceutical Sciences, Josai University, Saitama 
      350-0295, Japan.
FAU - Matsuzaki, Hirokazu
AU  - Matsuzaki H
AD  - Laboratory of Pharmacology, School of Pharmaceutical Sciences, Faculty of 
      Pharmaceutical Sciences, Josai University, Saitama 350-0295, Japan.
FAU - Okazaki, Mari
AU  - Okazaki M
AD  - Laboratory of Pharmacology, School of Pharmaceutical Sciences, Faculty of 
      Pharmaceutical Sciences, Josai University, Saitama 350-0295, Japan.
FAU - Hibino, Yasuhide
AU  - Hibino Y
AD  - Laboratory of Immunobiochemistry, Department of Clinical Dietetics & Human 
      Nutrition, Faculty of Pharmaceutical Sciences, Josai University, Saitama 
      350-0295, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151119
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Diabetes Mellitus, Experimental/complications/*drug 
      therapy/genetics/physiopathology
MH  - Etanercept/*administration & dosage
MH  - Humans
MH  - Infarction, Middle Cerebral Artery/drug therapy/genetics/physiopathology
MH  - Inflammation/*drug therapy/genetics/pathology
MH  - Ischemic Attack, Transient/complications/*drug therapy/genetics/physiopathology
MH  - Neuroprotective Agents
MH  - Rats
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors/metabolism
PMC - PMC4668299
EDAT- 2015/12/15 06:00
MHDA- 2016/09/16 06:00
PMCR- 2015/11/19
CRDT- 2015/12/15 06:00
PHST- 2015/08/17 00:00 [received]
PHST- 2015/10/28 00:00 [accepted]
PHST- 2015/12/15 06:00 [entrez]
PHST- 2015/12/15 06:00 [pubmed]
PHST- 2016/09/16 06:00 [medline]
PHST- 2015/11/19 00:00 [pmc-release]
AID - 10.1155/2015/189292 [doi]
PST - ppublish
SO  - Biomed Res Int. 2015;2015:189292. doi: 10.1155/2015/189292. Epub 2015 Nov 19.